Collegium Pharmaceutical (NASDAQ:COLL) Trading Down 3.7%

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) traded down 3.7% during trading on Monday . The company traded as low as $34.73 and last traded at $34.73. 18,395 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 448,760 shares. The stock had previously closed at $36.08.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Needham & Company LLC cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Piper Sandler cut Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price target for the company. in a research note on Friday, May 10th. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the company from $41.00 to $44.00 in a research note on Friday, June 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $40.75.

Collegium Pharmaceutical Trading Down 7.8 %

The business has a 50 day moving average of $32.64 and a 200-day moving average of $34.62. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The firm has a market capitalization of $1.09 billion, a P/E ratio of 14.25 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The business had revenue of $144.92 million for the quarter, compared to the consensus estimate of $147.04 million. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.68 EPS for the current fiscal year.

Insider Transactions at Collegium Pharmaceutical

In other news, Director Garen G. Bohlin sold 28,985 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now directly owns 44,775 shares in the company, valued at $1,446,232.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Garen G. Bohlin sold 28,985 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now directly owns 44,775 shares in the company, valued at $1,446,232.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 19,710 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the sale, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The disclosure for this sale can be found here. Insiders sold 105,502 shares of company stock valued at $3,540,796 in the last ninety days. 3.98% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently added to or reduced their stakes in COLL. Assenagon Asset Management S.A. increased its holdings in Collegium Pharmaceutical by 411.1% during the second quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock worth $11,661,000 after buying an additional 291,286 shares during the last quarter. LSV Asset Management increased its holdings in Collegium Pharmaceutical by 188.7% during the first quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock worth $14,773,000 after buying an additional 248,751 shares during the last quarter. New York State Common Retirement Fund increased its holdings in Collegium Pharmaceutical by 1,475.5% during the fourth quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock worth $6,190,000 after buying an additional 188,347 shares during the last quarter. Federated Hermes Inc. increased its holdings in Collegium Pharmaceutical by 76.0% during the fourth quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock worth $6,549,000 after buying an additional 91,911 shares during the last quarter. Finally, Third Avenue Management LLC acquired a new position in Collegium Pharmaceutical during the fourth quarter worth $2,558,000.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.